Hypoglycemia—also called low blood glucose or low blood sugar—is usually defined as a plasma glucose level < 70 mg/dL (3.9 mmol/L) and occurs when blood glucose drops below normal levels. It is a common side effect of diabetes therapy, resulting in a lack of adequate cerebral glucose supply, leading to a range of neurogenic and neuroglycopenic symptoms.
Hypoglycemia may also seldom result from certain causes such as pancreatic or non-islet cell tumors, autoimmune conditions, organ failure, endocrine disease, inborn errors of metabolism, dietary toxins, alcohol consumption, stress, infections and miscellaneous conditions (such as sepsis, starvation, severe excessive exercise).
Get FREE sample copy at: https://www.delveinsight.com/sample-request/hypoglycemia-market
The Hypoglycemia market report also covers emerging drugs, current treatment practices, Hypoglycemia market share of the individual therapies, current and forecasted Hypoglycemia Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Hypoglycemia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Hypoglycemia Market Key Facts
-
According to Davis et al. (2018), hypoglycemia is less frequent in T2DM patients, but T2DM patients treated intensively with insulin can also experience hypoglycemic episodes with a prevalence of ≥80%.
-
According to a meta-analysis study, the prevalence of hypoglycemia was estimated as 45% for mild/moderate and 6% for severe cases in type 2 diabetes patients (Edridge, n.d.).
-
As per an article by Edward (n.d.) titled “Low Blood Sugar a Potential Complication after Weight-Loss Surgery,“ around 34% of gastric bypass patients developed severe hypoglycemia after being given a bolus of sugar.
Key Benefits of Hypoglycemia Market Report
-
Hypoglycemia market report provides an in-depth analysis of Hypoglycemia Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets, i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.
-
The Hypoglycemia market report will help in developing business strategies by understanding the Hypoglycemia Market trends & developments, key players, and future market competition that will shape and drive the Hypoglycemia market in the upcoming years.
-
The Hypoglycemia market report covers Hypoglycemia current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
-
The report provides a detailed assessment of the Hypoglycemia market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Hypoglycemia market size is expected to increase during the forecast period owing to the launch of upcoming therapies.
The Hypoglycemia market outlook section of the report helps to build a detailed comprehension of the historic, current and forecasted Hypoglycemia market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Hypoglycemia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Hypoglycemia Epidemiology
The Hypoglycemia epidemiology section covers insights about the historical and current Hypoglycemia patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Hypoglycemia Epidemiology Segmentation –
-
Total Prevalent cases of Hypoglycemia
-
Severity-Specific cases of Hypoglycemia
-
Age-Specific cases of Hypoglycemia
-
Diagnosed and Treatable cases of Hypoglycemia
Hypoglycemia Drugs Uptake and Key Market Players
The Hypoglycemia Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hypoglycemia market or expected to get launched in the market during the study period. The analysis covers Hypoglycemia market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Hypoglycemia Companies:
Zealand Pharma
Novo Nordisk
Eiger BioPharmaceuticals
Xeris Pharmaceuticals
And many others
Hypoglycemia Therapies covered in the report include:
Dasiglucagon
Avexitide
And many more.
Table of Content
1. Key Insights
2. Executive Summary
3. Hypoglycemia Competitive Intelligence Analysis
4. Hypoglycemia Market Overview at a Glance
5. Hypoglycemia Disease Background and Overview
6. Hypoglycemia Patient Journey
7. Hypoglycemia Epidemiology and Patient Population
8. Hypoglycemia Treatment Algorithm, Current Treatment, and Medical Practices
9. Hypoglycemia Unmet Needs
10. Key Endpoints of Hypoglycemia Treatment
11. Hypoglycemia Marketed Products
12. Hypoglycemia Emerging Therapies
13. Hypoglycemia Seven Major Market Analysis
14. Attribute Analysis
15. Hypoglycemia Market Outlook (7 major markets)
16. Hypoglycemia Access and Reimbursement Overview
17. KOL Views on the Hypoglycemia Market.
18. Hypoglycemia Market Drivers
19. Hypoglycemia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/hypoglycemia-market
Latest Reports By DelveInsight
Hypoglycemia Pipeline Insights
Hypoglycemia Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Hypoglycemia market.
Healthcare Blogs –
Benign Prostatic Hyperplasia Devices Market Dynamics
As per DelveInsight’s Benign Prostatic Hyperplasia (BPH) Devices Market analysis, the total eligible patient population for BPH in 7MM is expected to increase at a CAGR of 2.58% during the study period 2018-2026. The key companies operating in the Benign Prostatic Hyperplasia (BPH) market include Olympus Medical Americas, Butterfly Medical, SRS Medical, Teleflex Interventional Urology, Urotronic, Inc., Zenflow, Inc., ProArc Medical, and Medion Biodesign. For more detailed information, visit Benign Prostatic Hyperplasia (BPH) Devices Market.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/